other public and private entities that apply for COPS Office grants or cooperative agreements will be asked to complete the COPS Application Package. The COPS Application Package includes all of the necessary forms and instructions that an applicant needs to review and complete to apply for COPS grant funding. The package is used as a standard template for all COPS programs.

(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that 5000 respondents annually will complete the form within 11 hours.

(6) An estimate of the total public burden (in hours) associated with the collection: There are an estimated 55,000 total annual burden hours associated with this collection.

If additional information is required contact: Jerri Murray, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE., Washington DC 20530.

Dated: November 12, 2013.

Jerri Murray,
Department Clearance Officer for PRA, U.S. Department of Justice.

[FR Doc. 2013–27467 Filed 11–15–13; 8:45 am]
BILLING CODE 4410–AT–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application: Johnson Matthey, Inc.

Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this notice is that on September 5, 2013, Johnson Matthey, Inc., Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coca Leaves (9040)</td>
<td>II</td>
</tr>
<tr>
<td>Thebaine (9333)</td>
<td>II</td>
</tr>
<tr>
<td>Opium (9600)</td>
<td>II</td>
</tr>
<tr>
<td>Noroxymorphone (9668)</td>
<td>II</td>
</tr>
<tr>
<td>Poppy Straw Concentrate (9670)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substances as raw materials, to be used in the manufacture of bulk controlled substances, for distribution to its customers.

Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007).

In reference to the non-narcotic raw material, the company plans to import gram amounts to be used as reference standards for sale to its customers. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 18, 2013.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. § 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: November 4, 2013.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013–27448 Filed 11–15–13; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application: Cerilliant Corporation

Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this notice is that on July 16, 2013, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665–2402, made application to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methaqualone (2565)</td>
<td>I</td>
</tr>
<tr>
<td>JWH–250 (6250)</td>
<td>I</td>
</tr>
<tr>
<td>SR–18 also known as RCS–8– (7008).</td>
<td></td>
</tr>
<tr>
<td>XLR11 (7011)</td>
<td>I</td>
</tr>
<tr>
<td>JWH–019 (7019)</td>
<td>I</td>
</tr>
<tr>
<td>AKB48 (7046)</td>
<td>I</td>
</tr>
<tr>
<td>JWH–081 (7081)</td>
<td>I</td>
</tr>
<tr>
<td>SR–19 also known as RCS–4– (7104).</td>
<td></td>
</tr>
<tr>
<td>JWH–122 (7122)</td>
<td>I</td>
</tr>
<tr>
<td>UR–144 (7144)</td>
<td>I</td>
</tr>
<tr>
<td>AM–2201 (7201)</td>
<td>I</td>
</tr>
<tr>
<td>JWH–203 (7203)</td>
<td>I</td>
</tr>
<tr>
<td>Parahexyl (7374)</td>
<td>I</td>
</tr>
<tr>
<td>2C–T–2 (7385)</td>
<td>I</td>
</tr>
<tr>
<td>JWH–398 (7398)</td>
<td>I</td>
</tr>
<tr>
<td>5-Methoxy-3,4-methylenedioxy- (7401).</td>
<td></td>
</tr>
<tr>
<td>N-Hydroxy-3,4-methylenedioxy- (7402).</td>
<td></td>
</tr>
<tr>
<td>Bufotetine (7433)</td>
<td>I</td>
</tr>
<tr>
<td>N-Ethyl-1-phenylcyclohexylamine (7458).</td>
<td></td>
</tr>
<tr>
<td>1-(1-Phenylcyclohexyl)pyrrolidine (7470).</td>
<td></td>
</tr>
<tr>
<td>2C–D (7508)</td>
<td>I</td>
</tr>
<tr>
<td>2C–E (7509)</td>
<td>I</td>
</tr>
<tr>
<td>2C–H (7517)</td>
<td>I</td>
</tr>
<tr>
<td>2C–I (7518)</td>
<td>I</td>
</tr>
<tr>
<td>2C–C (7519)</td>
<td>I</td>
</tr>
<tr>
<td>2C–N (7521)</td>
<td>I</td>
</tr>
<tr>
<td>2C–P (7524)</td>
<td>I</td>
</tr>
<tr>
<td>2C–T–4 (7532)</td>
<td>I</td>
</tr>
<tr>
<td>AM–694 (7694)</td>
<td>I</td>
</tr>
<tr>
<td>Codeine methylbromide (9070)</td>
<td>I</td>
</tr>
<tr>
<td>Acetylketamidol (9061)</td>
<td>I</td>
</tr>
<tr>
<td>Allylpropion (9062)</td>
<td>I</td>
</tr>
<tr>
<td>Alphacetyketamidol except levo- (9603).</td>
<td></td>
</tr>
<tr>
<td>Alphamethylketamidol (9604)</td>
<td>I</td>
</tr>
<tr>
<td>Alphamethadol (9605)</td>
<td>I</td>
</tr>
<tr>
<td>Benzethidol (9606)</td>
<td>I</td>
</tr>
<tr>
<td>Betacetamidol (9607)</td>
<td>I</td>
</tr>
<tr>
<td>Betameprodol (9608)</td>
<td>I</td>
</tr>
<tr>
<td>Betameprodol (9611)</td>
<td>I</td>
</tr>
<tr>
<td>Betameprodol (9611)</td>
<td>I</td>
</tr>
<tr>
<td>Beta-hydroxydihydromorphine (9672)</td>
<td>I</td>
</tr>
<tr>
<td>Norcetylketamidol (9633)</td>
<td>I</td>
</tr>
<tr>
<td>Normorphamidol (9635)</td>
<td>I</td>
</tr>
<tr>
<td>Para-fluoroanfentan (9813)</td>
<td>I</td>
</tr>
<tr>
<td>3-Methylfentanyl (9813)</td>
<td>I</td>
</tr>
<tr>
<td>Alpha-fentanyl (9814)</td>
<td>I</td>
</tr>
<tr>
<td>Acetyl-alpha-fentanyl (9815)</td>
<td>I</td>
</tr>
<tr>
<td>Beta-hydroxyfentanyl (9830)</td>
<td>I</td>
</tr>
<tr>
<td>Beta-hydroxy-3-methylfentanyl (9831).</td>
<td></td>
</tr>
<tr>
<td>Alpha-methylketamidol (9832)</td>
<td>I</td>
</tr>
<tr>
<td>3-Methylthiofentanyl (9833)</td>
<td>I</td>
</tr>
<tr>
<td>Thiofentanyl (9835)</td>
<td>I</td>
</tr>
<tr>
<td>Lisdexamfetamidol (1205)</td>
<td>I</td>
</tr>
<tr>
<td>Glutethimide (2560)</td>
<td>I</td>
</tr>
<tr>
<td>Nabilone (7379)</td>
<td>I</td>
</tr>
</tbody>
</table>